[225Ac]Ac-PSMA-617 mutational landscape in circulating tumor DNA (ctDNA): early clinical outcome prediction in metastatic castration-resistant prostate cancer

被引：0
|
作者：
Amghar, M. [1 ]
Rausch, T. [2 ]
Hielscher, T. [1 ]
Ozgur, H. [2 ]
Roscher, M. [1 ]
Bauder-Wuest, U. [1 ]
Schick, M. [1 ]
Remde, Y. [1 ]
Bakos, G. [1 ]
Schaefer, M. [1 ]
Bruchertseifer, F. [3 ]
Morgenstern, A. [3 ]
Benes, V. [2 ]
Kratochwil, C. [4 ]
Benesova-Schaefer, M. [1 ]
机构：
[1] DKFZ, Heidelberg, Germany
[2] EMBL, Heidelberg, Germany
[3] Joint Res Ctr JRC, European Commiss, Karlsruhe, Germany
[4] Univ Hosp, Dept Nucl Med, Heidelberg, Germany
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2023年 / 50卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP-719
引用
收藏
页码：S326 / S326
页数：1
相关论文
共 50 条
  • [41] 225Ac-PSMA-617 targeted alpha therapy after Docetaxel based chemotherapy in the patients of metastatic castration resistant prostate cancer
    Sen, Ishita
    Pant, Vineet
    Thakral, Parul
    Raina, Vinod
    Das, Subha
    Sharma, Kanchan
    Manda, Divya
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [42] Clinical Outcomes and Contribution to Progression-Free Survival of Radionuclide Therapy with 225Ac-PSMA in Metastatic Castration-Resistant Prostate Cancer (mCDPK)
    Beydagi, G.
    Selcuk, N. Alan
    Demirci, E.
    Ocak, M.
    Toklu, T.
    Akcay, K.
    Caner, B.
    Kabasakal, L.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S131 - S131
  • [43] Baseline Imaging Derived Factors of Response Following [225Ac]Ac-J591 Therapy in Metastatic Castration-Resistant Prostate Cancer: A Lesion Level Analysis
    Stangl-Kremser, Judith
    Ricaurte-Fajardo, Andres
    Huicochea Castellanos, Sandra
    Martinez-Fundichely, Alexander
    Sun, Michael
    Osborne, Joseph R.
    Nauseef, Jones T.
    Tagawa, Scott T.
    Bander, Neil H.
    PROSTATE, 2025, 85 (05): : 502 - 509
  • [44] Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer
    Sonpavde, Guru
    Agarwal, Neeraj
    Pond, Gregory Russell
    Nagy, Rebecca J.
    Nussenzveig, Roberto H.
    Hahn, Andrew W.
    Sartor, Oliver
    Gourdin, Theodore Stewart
    Nandagopal, Lakshminarayanan
    Ledet, Elisa M.
    Naik, Gurudatta
    Armstrong, Andrew J.
    Wang, Jue
    Bilen, Mehmet Asim
    Gupta, Shilpa
    Grivas, Petros
    Pal, Sumanta K.
    Lanman, Richard B.
    Talasaz, AmirAli
    Lilly, Michael B.
    CANCER, 2019, 125 (09) : 1459 - 1469
  • [45] Circulating tumor DNA fraction (ctDNA%) to independently predict for clinical outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
    Maurice-Dror, Corinne
    Fonseca, Nicolette
    Herberts, Cameron
    Fan, William
    Wyatt, Alexander W.
    Chi, Kim N.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [46] Simple method for production and quality control of 225Ac- PSMA-617 for the targeted alpha therapy of castration-resistant prostate cancer.
    Khoshhosn, H.
    Dayeni, M.
    Pirdadeh, M.
    Ghapanvari, M.
    Tavakoli, Y.
    Samizadeh, M.
    Mazidi, M.
    Nami, R.
    Soltani, N.
    Movahhed, H.
    Gravand, A.
    Sarabi, A.
    Davarpanah, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S674 - S675
  • [47] Evolving role of 225Ac-PSMA radioligand therapy in metastatic castration-resistant prostate cancer—a systematic review and meta-analysis
    Swayamjeet Satapathy
    Ashwani Sood
    Chandan Krushna Das
    Bhagwant Rai Mittal
    Prostate Cancer and Prostatic Diseases, 2021, 24 : 880 - 890
  • [48] SatisfACtion: a phase 1/2 study of [225Ac]Ac-PSMA-R2 in patients with PSMA-positive metastatic castration-resistant prostate cancer with or without previous [177Lu]Lu-PSMA radioligand therapy
    Kraeber-Bodere, F.
    Mahammedi, H.
    Giraudet, A.
    Wehbe, J.
    Wilke, C.
    Olivier, P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S280 - S280
  • [49] Association of changing bone metastatic (mets) patterns with dynamics of circulating tumor DNA (ctDNA) in metastatic castration-resistant prostate cancer (mCRPC).
    Conteduca, Vincenza
    Scarpi, Emanuela
    Rossi, Alice
    Ferroni, Fabio
    Gurioli, Giorgia
    Bleve, Sara
    Gianni, Caterina
    Schepisi, Giuseppe
    Brighi, Nicole
    Lolli, Cristian
    Cursano, Maria Concetta
    Virga, Alessandra
    Casadei, Chiara
    Altavilla, Amelia
    Farolfi, Alberto
    Ulivi, Paola
    Barone, Domenico
    Matteucci, Federica
    Paganelli, Giovanni
    De Giorgi, Ugo
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [50] Favorable Response of 225Ac-PSMA in the Treatment of Castration-Resistant Prostate Cancer With High Bone Metastasis Burden
    Wang, Yudi
    Hua, Qingchu
    Zhang, Yu
    Wang, Wei
    Chen, Yue
    CLINICAL NUCLEAR MEDICINE, 2024, 49 (07) : 674 - 676
12345